Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma

Sa Ra Lee, Kyong Wook Yi, Jae Yen Song, Seok Kyo Seo, Dong Yun Lee, Si Hyun Cho, Sung Hoon Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Dienogest (DNG) is a progestin with highly selective progesterone activity and minimal androgenic activity and is helpful in reducing endometriosis-related pain. This study assessed the long-term efficacy and safety and recurrence rate of endometrioma with DNG use beyond 12 months of treatment. A retrospective cohort study was conducted with data collected from 7 university-affiliated hospitals and included a total of 514 women with ovarian endometrioma. All patients received 2 mg of oral DNG daily for at least 48 weeks postoperatively. During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed. The average period of DNG administration in this study was 72.2 ± 5.2 weeks (range: 48-164). The recurrence rate of endometrioma was 1.8% (9 of 514), and the median duration to recurrence was 58 weeks (range: 24-76). Pain was described as overall improved by 82.2% of patients; 61.6% stated the pain was “improved” and 20.6% reported “much improved.” The mean VAS score was 4.9 at baseline and significantly decreased to 2.68, 2.2, 1.6, and 2.6 at 12, 24, 48, and 96 weeks. Amenorrhea rate was 58.3% in the first 12 weeks and increased to 86.4% at 72 weeks. Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms.

Original languageEnglish
Pages (from-to)341-346
Number of pages6
JournalReproductive Sciences
Volume25
Issue number3
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

dienogest
Endometriosis
Safety
Recurrence
Pain
Dysmenorrhea
Amenorrhea
Progestins
Visual Analog Scale
Progesterone
Cohort Studies
Retrospective Studies

Keywords

  • Dienogest
  • endometriosis
  • progestin

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma. / Lee, Sa Ra; Yi, Kyong Wook; Song, Jae Yen; Seo, Seok Kyo; Lee, Dong Yun; Cho, Si Hyun; Kim, Sung Hoon.

In: Reproductive Sciences, Vol. 25, No. 3, 01.03.2018, p. 341-346.

Research output: Contribution to journalArticle

Lee, Sa Ra ; Yi, Kyong Wook ; Song, Jae Yen ; Seo, Seok Kyo ; Lee, Dong Yun ; Cho, Si Hyun ; Kim, Sung Hoon. / Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma. In: Reproductive Sciences. 2018 ; Vol. 25, No. 3. pp. 341-346.
@article{2fd37fae8cc44a0d8e8f5f833f6e9e47,
title = "Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma",
abstract = "Dienogest (DNG) is a progestin with highly selective progesterone activity and minimal androgenic activity and is helpful in reducing endometriosis-related pain. This study assessed the long-term efficacy and safety and recurrence rate of endometrioma with DNG use beyond 12 months of treatment. A retrospective cohort study was conducted with data collected from 7 university-affiliated hospitals and included a total of 514 women with ovarian endometrioma. All patients received 2 mg of oral DNG daily for at least 48 weeks postoperatively. During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed. The average period of DNG administration in this study was 72.2 ± 5.2 weeks (range: 48-164). The recurrence rate of endometrioma was 1.8{\%} (9 of 514), and the median duration to recurrence was 58 weeks (range: 24-76). Pain was described as overall improved by 82.2{\%} of patients; 61.6{\%} stated the pain was “improved” and 20.6{\%} reported “much improved.” The mean VAS score was 4.9 at baseline and significantly decreased to 2.68, 2.2, 1.6, and 2.6 at 12, 24, 48, and 96 weeks. Amenorrhea rate was 58.3{\%} in the first 12 weeks and increased to 86.4{\%} at 72 weeks. Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms.",
keywords = "Dienogest, endometriosis, progestin",
author = "Lee, {Sa Ra} and Yi, {Kyong Wook} and Song, {Jae Yen} and Seo, {Seok Kyo} and Lee, {Dong Yun} and Cho, {Si Hyun} and Kim, {Sung Hoon}",
year = "2018",
month = "3",
day = "1",
doi = "10.1177/1933719117725820",
language = "English",
volume = "25",
pages = "341--346",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma

AU - Lee, Sa Ra

AU - Yi, Kyong Wook

AU - Song, Jae Yen

AU - Seo, Seok Kyo

AU - Lee, Dong Yun

AU - Cho, Si Hyun

AU - Kim, Sung Hoon

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Dienogest (DNG) is a progestin with highly selective progesterone activity and minimal androgenic activity and is helpful in reducing endometriosis-related pain. This study assessed the long-term efficacy and safety and recurrence rate of endometrioma with DNG use beyond 12 months of treatment. A retrospective cohort study was conducted with data collected from 7 university-affiliated hospitals and included a total of 514 women with ovarian endometrioma. All patients received 2 mg of oral DNG daily for at least 48 weeks postoperatively. During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed. The average period of DNG administration in this study was 72.2 ± 5.2 weeks (range: 48-164). The recurrence rate of endometrioma was 1.8% (9 of 514), and the median duration to recurrence was 58 weeks (range: 24-76). Pain was described as overall improved by 82.2% of patients; 61.6% stated the pain was “improved” and 20.6% reported “much improved.” The mean VAS score was 4.9 at baseline and significantly decreased to 2.68, 2.2, 1.6, and 2.6 at 12, 24, 48, and 96 weeks. Amenorrhea rate was 58.3% in the first 12 weeks and increased to 86.4% at 72 weeks. Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms.

AB - Dienogest (DNG) is a progestin with highly selective progesterone activity and minimal androgenic activity and is helpful in reducing endometriosis-related pain. This study assessed the long-term efficacy and safety and recurrence rate of endometrioma with DNG use beyond 12 months of treatment. A retrospective cohort study was conducted with data collected from 7 university-affiliated hospitals and included a total of 514 women with ovarian endometrioma. All patients received 2 mg of oral DNG daily for at least 48 weeks postoperatively. During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed. The average period of DNG administration in this study was 72.2 ± 5.2 weeks (range: 48-164). The recurrence rate of endometrioma was 1.8% (9 of 514), and the median duration to recurrence was 58 weeks (range: 24-76). Pain was described as overall improved by 82.2% of patients; 61.6% stated the pain was “improved” and 20.6% reported “much improved.” The mean VAS score was 4.9 at baseline and significantly decreased to 2.68, 2.2, 1.6, and 2.6 at 12, 24, 48, and 96 weeks. Amenorrhea rate was 58.3% in the first 12 weeks and increased to 86.4% at 72 weeks. Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms.

KW - Dienogest

KW - endometriosis

KW - progestin

UR - http://www.scopus.com/inward/record.url?scp=85042304201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042304201&partnerID=8YFLogxK

U2 - 10.1177/1933719117725820

DO - 10.1177/1933719117725820

M3 - Article

C2 - 29161960

AN - SCOPUS:85042304201

VL - 25

SP - 341

EP - 346

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 3

ER -